AI Science Tracker

Retrosynthetic software finds experimentally validated supply routes for umifenovir

University of Michigan; MilliporeSigma; Entos, Inc. · 16 Dec 2021 · chemistry

Discovery

Retrosynthetic software finds experimentally validated supply routes for umifenovir

Retrosynthesis software proposed alternative chemical supply routes for the antiviral umifenovir and eleven other antiviral and anti-inflammatory drugs. The authors experimentally validated four routes to umifenovir and one route to bromhexine, one of which converts six C-H bonds. The work is a proof of route feasibility for supply-chain resilience, not a new therapeutic claim.

Technology: Computer-aided retrosynthesis software with exclusion of known starting materials

Publication: Peer-reviewed paper · Test context: direct test. Catalog categories, not an evidence grade.

Result, AI contribution and limits

Evidence context (descriptions follow the cited sources; test type is a catalog classification):

  • Publication status: Peer-reviewed paper
  • Test type: direct test
  • Tested: The authors experimentally validated four routes to umifenovir and one route to bromhexine proposed by the software.
  • Still unknown: Not reported.
  • AI role: Retrosynthesis software proposed alternative supply routes for umifenovir and other antiviral and anti-inflammatory drugs.

Evidence sources: https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=DOI:10.1038/s41467-021-27547-3&resultType=core&format=json

The legacy label “Not reported” does not distinguish information absent from reviewed material from information not assessed. It is not a scientific finding of absence.

Source checked · editorial details

The source page was checked against this entry. Independent confirmation is not assessed by this label.

Source type: paper. Paper: not linked in this catalog; this does not mean no paper exists.

Review scope and date are not recorded; source checked does not establish full-text review.

Citations: at percentile 87 of works of the same type, year and subfield (OpenAlex work metrics, 38 citations; as of 15 Nov 2026). Attention, not a measure of correctness; not part of the score.

Editorial assessment: Impact 3/5 · Validation 3/5 · Novelty 3/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.

Follow-up and relationships

No follow-up recorded; this is not a claim that no follow-up exists.

Follow-up review scope and date are not recorded.

No source-supported relationships recorded.

Open in the full catalog for filters, charts and related discoveries.